[go: up one dir, main page]

WO1998004289A3 - Composition pharmaceutique contenant un antagoniste 5ht2c et un antagoniste d¿2? - Google Patents

Composition pharmaceutique contenant un antagoniste 5ht2c et un antagoniste d¿2? Download PDF

Info

Publication number
WO1998004289A3
WO1998004289A3 PCT/EP1997/004159 EP9704159W WO9804289A3 WO 1998004289 A3 WO1998004289 A3 WO 1998004289A3 EP 9704159 W EP9704159 W EP 9704159W WO 9804289 A3 WO9804289 A3 WO 9804289A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
5ht2c
pharmaceutical composition
composition containing
compounds
Prior art date
Application number
PCT/EP1997/004159
Other languages
English (en)
Other versions
WO1998004289A2 (fr
Inventor
Thomas Paul Blackburn
Original Assignee
Smithkline Beecham Plc
Thomas Paul Blackburn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL12821997A priority Critical patent/IL128219A0/xx
Priority to JP10508522A priority patent/JP2000516924A/ja
Priority to NZ333813A priority patent/NZ333813A/xx
Priority to AU42972/97A priority patent/AU725817B2/en
Priority to HU9903619A priority patent/HUP9903619A3/hu
Priority to PL97331426A priority patent/PL331426A1/xx
Application filed by Smithkline Beecham Plc, Thomas Paul Blackburn filed Critical Smithkline Beecham Plc
Priority to BR9710568A priority patent/BR9710568A/pt
Priority to CA002261813A priority patent/CA2261813A1/fr
Priority to EP97918947A priority patent/EP0936924A2/fr
Publication of WO1998004289A2 publication Critical patent/WO1998004289A2/fr
Publication of WO1998004289A3 publication Critical patent/WO1998004289A3/fr
Priority to NO990322A priority patent/NO990322L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a trait à des combinaisons de composés possédant une activité antagoniste 5HT2C et D2, à des composés possédant une activité sur ces deux récepteurs, à des compositions pharmaceutiques contenant lesdits composés, et à leur utilisation dans le traitement de la schizophrénie.
PCT/EP1997/004159 1996-07-26 1997-07-22 Composition pharmaceutique contenant un antagoniste 5ht2c et un antagoniste d¿2? WO1998004289A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP10508522A JP2000516924A (ja) 1996-07-26 1997-07-22 ５ｈｔ▲下２ｃ▼アンタゴニストおよびｄ▲下２▼アンタゴニストを含む医薬組成物
NZ333813A NZ333813A (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist
AU42972/97A AU725817B2 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist
HU9903619A HUP9903619A3 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
PL97331426A PL331426A1 (en) 1996-07-26 1997-07-22 Pharmaceutic composition containing the 5ht2c antagonist and the d2 antagonist
IL12821997A IL128219A0 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
BR9710568A BR9710568A (pt) 1996-07-26 1997-07-22 Composi- o farmac-utica contendo um antagonista 5Hht2c e um antagonista d2
CA002261813A CA2261813A1 (fr) 1996-07-26 1997-07-22 Composition pharmaceutique contenant un antagoniste 5ht2c et un antagoniste d2
EP97918947A EP0936924A2 (fr) 1996-07-26 1997-07-22 Composition pharmaceutique contenant un antagoniste 5ht 2c? et un antagoniste d 2?
NO990322A NO990322L (no) 1996-07-26 1999-01-25 Farmas°ytisk blanding inneholdende en 5HT2c-antagonist og en D2-antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615767.2A GB9615767D0 (en) 1996-07-26 1996-07-26 Novel treatment
GB9615767.2 1996-07-26

Publications (2)

Publication Number Publication Date
WO1998004289A2 WO1998004289A2 (fr) 1998-02-05
WO1998004289A3 true WO1998004289A3 (fr) 1998-03-19

Family

ID=10797573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/004159 WO1998004289A2 (fr) 1996-07-26 1997-07-22 Composition pharmaceutique contenant un antagoniste 5ht2c et un antagoniste d¿2?

Country Status (19)

Country Link
EP (1) EP0936924A2 (fr)
JP (1) JP2000516924A (fr)
KR (1) KR20000029564A (fr)
CN (1) CN1230894A (fr)
AR (1) AR008083A1 (fr)
AU (1) AU725817B2 (fr)
BR (1) BR9710568A (fr)
CA (1) CA2261813A1 (fr)
CO (1) CO5031292A1 (fr)
CZ (1) CZ23799A3 (fr)
GB (1) GB9615767D0 (fr)
HU (1) HUP9903619A3 (fr)
IL (1) IL128219A0 (fr)
NO (1) NO990322L (fr)
NZ (1) NZ333813A (fr)
PL (1) PL331426A1 (fr)
TR (1) TR199900140T2 (fr)
WO (1) WO1998004289A2 (fr)
ZA (1) ZA976593B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
AU757874B2 (en) 1998-11-23 2003-03-06 Sepracor, Inc. 2-hydroxymethylolanzapine compositions and methods
US6348455B1 (en) 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
ATE253364T1 (de) * 1998-11-23 2003-11-15 Sepracor Inc Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
US6395727B1 (en) 1999-03-18 2002-05-28 The Cincinnati Children's Hospital Research Foundation Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications
HK1048440A1 (zh) * 1999-05-19 2003-04-04 阿斯特拉曾尼卡有限公司 治療體重增加的方法
WO2005013969A1 (fr) * 2003-07-15 2005-02-17 Janssen Pharmaceutica N.V. Agent antipsychotique a proprietes favorisant la socialisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029316A1 (fr) * 1995-03-19 1996-09-26 Wikstroem Haakan Esters de sulfone constituant de nouveaux analogues d'iso-clozapine et structures apparentees: neuroleptiques atypiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029316A1 (fr) * 1995-03-19 1996-09-26 Wikstroem Haakan Esters de sulfone constituant de nouveaux analogues d'iso-clozapine et structures apparentees: neuroleptiques atypiques

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.M.J.MONTGOMERY ET AL.: "Potentiation of the effects of raclopride on sucrose consumption by the 5-HT2 antagonist ritanserin", PSYCHOPHARMACOLOGY, vol. 123, no. 1, 1996, pages 98 - 102, XP002051726 *
ARIEL Y. DEUTCH: "Mechanism of action of atypical antipsychotic drugs", SCHIZOPHREN. RES., vol. 4, no. 2, 1991, pages 121 - 156, XP002051731 *
D.S.BALDWIN ET AL.: "First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia", INT.CLIN.PSYCHOPHARMACOL., vol. 10, no. 4, 1995, pages 239 - 244, XP002051729 *
E.MEIER ET AL.: "The atypical neuroleptic, sertindole, is a 5-HT2C receptor antagonist", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 20, no. 1-2, 1994, pages 1543, XP002051725 *
FRANK P. BYMASTER ET AL.: "Radioreceptor binding profile of the atypical antipsychotic olanzapine", NEUROPSYCHOPHARMACOLOGY, vol. 14, no. 2, February 1996 (1996-02-01), pages 87 - 96, XP002051728 *
HERBERT Y. MELTZER: "An overview of the mechanism of action of clozapine", J.CLIN.PSYCHIATRY, vol. 55, no. 9 suppl. B, 1994, pages 47 - 52, XP002051727 *
T.F.SEEGER ET AL.: "Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity", J.PHARMACOL.EXP.THER., vol. 275, no. 1, 1995, pages 101 - 113, XP002051730 *

Also Published As

Publication number Publication date
GB9615767D0 (en) 1996-09-04
ZA976593B (en) 1999-01-25
CN1230894A (zh) 1999-10-06
NO990322D0 (no) 1999-01-25
CA2261813A1 (fr) 1998-02-05
KR20000029564A (ko) 2000-05-25
AR008083A1 (es) 1999-12-09
NO990322L (no) 1999-03-24
AU4297297A (en) 1998-02-20
CZ23799A3 (cs) 1999-06-16
JP2000516924A (ja) 2000-12-19
CO5031292A1 (es) 2001-04-27
PL331426A1 (en) 1999-07-19
EP0936924A2 (fr) 1999-08-25
HUP9903619A2 (hu) 2000-10-28
TR199900140T2 (xx) 1999-03-22
IL128219A0 (en) 1999-11-30
HUP9903619A3 (en) 2001-03-28
WO1998004289A2 (fr) 1998-02-05
BR9710568A (pt) 1999-08-17
NZ333813A (en) 2000-07-28
AU725817B2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
HUP9900616A3 (en) Tricyclic compounds, their production, pharmaceutical compositions and use
IL125811A (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them and uses thereof in the preparation of a composition for inhibiting nos
IL115039A (en) Spiroazabicyclic compounds, their preparation and pharmaceutical compositions containing them
HUP9901199A3 (en) Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
HUP9801692A3 (en) Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
AU4075299A (en) N,n'-azobis-nitroazoles and analogs thereof as igniter compounds for use in energetic compositions
HUP9901243A3 (en) Quinazoline derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
IL113389A0 (en) 1,4-Benzodiazepine compounds, pharmaceutical compositions containing them, their preparation and use
HUP9700328A3 (en) Heteroaryl-oxazolidinones, process for their preparation, pharmaceutical compositions containing the same, their use and intermediates
HUP9902410A3 (en) Amidino derivatives, preparation and use as thrombin inhibitors thereof, pharmaceutical compositions containing these compounds
HUP0002272A3 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
HUP9900975A3 (en) Quinoxalinedione derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
IL116746A0 (en) Use of 3, 4-diphenyl chromans for the preparation of pharmaceutical compositions
IL112443A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
IL111011A0 (en) Bisbenzimidazole compounds, their preparation and pharmaceutical compositions containing them
HUT74746A (en) Pharmaceutical compositions containing p antagonist
WO1996023769A3 (fr) Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht¿2c?
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP9902166A3 (en) Substituted benzamide derivatives having anticonvulsant activity, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP0104834A3 (en) Sulphonyloxazolamines, their use, pharmaceutical compositions containing them and their preparation
HUP0001940A3 (en) Benzisothiazole derivatives, their use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197977.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 333813

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997918947

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2261813

Country of ref document: CA

Ref document number: 2261813

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-237

Country of ref document: CZ

Ref document number: PA/a/1999/000924

Country of ref document: MX

Ref document number: 1019997000622

Country of ref document: KR

Ref document number: 1999/00140

Country of ref document: TR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-237

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 09230367

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997918947

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997000622

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1997918947

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997000622

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997918947

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1999-237

Country of ref document: CZ